Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC), LivaNova (LIVN) and Theratechnologies (THTX).
Teladoc (TDOC)
Canaccord Genuity analyst Richard Close maintained a Buy rating on Teladoc yesterday and set a price target of $195.00. The company’s shares closed last Wednesday at $175.10.
According to TipRanks.com, Close is a 5-star analyst with an average return of 13.2% and a 59.3% success rate. Close covers the Technology sector, focusing on stocks such as Castlight Health, Health Catalyst, and Livongo Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $151.95 average price target, a -13.2% downside from current levels. In a report issued on April 15, Cowen & Co. also maintained a Buy rating on the stock with a $175.00 price target.
See today’s analyst top recommended stocks >>
LivaNova (LIVN)
Canaccord Genuity analyst Jason Mills maintained a Hold rating on LivaNova yesterday and set a price target of $50.00. The company’s shares closed last Wednesday at $53.53.
According to TipRanks.com, Mills is a top 100 analyst with an average return of 22.5% and a 70.4% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Merit Medical Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LivaNova with a $76.50 average price target.
Theratechnologies (THTX)
In a report released yesterday, Edward Nash from Canaccord Genuity reiterated a Buy rating on Theratechnologies, with a price target of $11.00. The company’s shares closed last Wednesday at $2.54.
According to TipRanks.com, Nash is a 4-star analyst with an average return of 6.6% and a 41.4% success rate. Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Galmed Pharmaceuticals, and Akero Therapeutics.
Currently, the analyst consensus on Theratechnologies is a Moderate Buy with an average price target of $5.68, implying a 127.2% upside from current levels. In a report issued on April 14, Echelon Wealth Partners also maintained a Buy rating on the stock with a C$11.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
